LAURUS Labs
Chemistry for Better Living

Press Release

FOR IMMEDIATE RELEASE

29 OCTOBER, 2026

Laurus Labs Announces H1 FY27 Results

Revenues at ₹ 4,233 Cr; EBITDA at ₹ 1,406 Cr, 33.2% margins

Hyderabad, October 29, 2026: Laurus Labs Ltd. (**Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028**), a leading research and development driven pharmaceutical and biotech company in India announces its Q2 & H1 FY27 results.

Financial Summary

[₹ Crore] except EPS amounts	2Q FY27	2Q FY26	Y-o-Y	1H FY27	1H FY26	Y-o-Y
Revenue	2,206	1,653	33%	4,233	3,223	31%
Gross Margins	*63.0%*	*59.9%*	*+3.1%*	*62.9%*	*59.6%*	*+3.3%*
EBITDA	762	429	+78%	1,406	818	+72%
EBITDA Margins	*34.5%*	*26.0%*	*+8.5%*	*33.2%*	*25.4%*	*+7.8%*
PBT	592	270	+119%	1,073	494	+117%
Net Profit	441	195	+126%	809	358	+126%
EPS (Diluted)	8.2	3.6	+128%	15.0	6.6	+127%

Dr. Satyanarayana Chava, Founder & Chief Executive Officer commented;

"Laurus achieved another record quarter of strong growth in Revenue and Profits, demonstrating the strength of our CDMO platform and Affordable Medicines portfolio as we execute on our transformation strategy. The company operationalized its first commercial scale peptide plant in Vizag utilizing cutting edge operating systems and a significant capacity expansion is already under progress to address surging demand for peptide therapeutics. We also made targeted investments in Oligonucleotides and peptide-resins technologies elevating our integrated CDMO offering.

Together this progress reflects our continued commitment on enhancing core capabilities, expanding capacities to deliver greater value for customers and stakeholders."

Corporate Office
Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India
T +91 40 6659 4333, 2342 0500/501 **F** +91 40 6659 4320

Registered Office
Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India
CIN : L24239AP2005PLC047518, **T** +91 891 682 1101, 1102, **F** +91 891 682 1103, E info@lauruslabs.com, **W** lauruslabs.com

V V Ravi Kumar, Executive Director & Chief Financial Officer commented;

"We continue to report strong operational execution for the quarter and made important progress in building strong foundation. Driven by sustained momentum across both CDMO and Affordable Medicine division We have achieved revenue of ₹ 2,206 Cr, representing 33% growth and EBITDA of ₹ 762 Cr, representing 78% growth. The EBITDA margins were strong at 34.5%, supported by improvement in capacity efficiency from growing commercial supplies. Gross margins improved by over 3% pts to 63% due to favorable segment mix.

During H1, we achieved ₹ 4,233 Cr in revenue, representing 31% growth and EBITDA of ₹ 1,406 Cr, representing 72% growth, resulting in 33.2% EBITDA margins expanding over 7.8% pts partly supported by Gross margin expansion. We advanced key CAPEX milestone across diversified growth projects and Our capital allocation strategy remains focused on prioritizing investments that support near and long-term growth."

Divisional Revenue Performance

[₹ Crore]	2Q FY27	2Q FY26	Y-o-Y	1H FY27	1H FY26	Y-o-Y
CDMO	**904**	**518**	**75%**	**1,774**	**1,040**	**71%**
Small molecules	875	471	86%	1,710	964	77%
Bio	29	47	-38%	64	76	-16%
Affordable Medicines	**1,302**	**1,135**	**15%**	**2,459**	**2,183**	**13%**
API	625	617	1%	1,280	1,254	2%
FDF	677	518	31%	1,179	929	27%
Total Revenue	**2,206**	**1,653**	**33%**	**4,233**	**3,223**	**31%**
ARV Revenue*	735	733	0.3%	1,404	1,380	2%

* Includes API and Formulation (FDF) combined revenue

Summary Highlights:

- Strong H1 performance; ₹ 4,233 Cr Revenue and 31% revenue growth
- Sustained strong growth in CDMO revenue driven by commercial supplies and steady momentum in Affordable Medicines division
- ₹ 1,406 Cr EBITDA with a margin of 33.2%, increased by 7.8% pts, contributed by higher CDMO revenue and improving operational leverage. Gross margins expanded by over 3.3% pts to 62.9%
- Q2 Revenue ₹ 2,206 Cr; +33% revenue growth, ₹ 762 Cr EBITDA; +78% growth resulted in a margin of 34.5%, Gross margins were at 63%
- Announced investments in two technology platforms to strengthen Integrated CDMO offering; Oligonucleotides and peptide-resins
- CAPEX % to Revenue reached 20%, reflecting sustained investment in expanding the manufacturing network and niche capabilities
- Declared Interim Dividend of ₹ 1.00/- per share

Divisional Highlights:

CDMO – Small molecules

- CDMO business reported revenue of ₹ 1,710 Cr, during H1FY27; increased by 77%
- Q2 Revenue of ₹ 875 Cr; increased by 86% Y/Y, driven by advancing late-stage clinical projects, commercial API supplies and ramp-up of new assets
- Sustained strong demand in complex/integrated small molecule offerings
- Inaugurated Peptide manufacturing facility in Vizag with total Solid Phase Peptide Synthesis (SPPS) capacity >16,000L and we are further expanding capacities to meet growing needs from various partners.
- Multiple large-scale API capacity construction in Vizag making good progress
- CDMO Pipeline continue to expand on high quality molecules and active projects spread across multiple technologies and by indications

BIO – Large molecules

- Bio business reported revenue of ₹ 64 Cr, during H1FY27; decreased by 16%
- Q2 Revenue of ₹ 29 Cr; decreased by 38% Y/Y due to campaign phasing
- Scaling enzymatic technology application across clinical and commercial API projects as part of integrated offerings
- LB-4 Fermentation manufacturing unit progressing as planned (>400kL) and set to be commissioned by 3QFY27; actively securing customer capacity commitments.

Affordable Medicines

- Affordable Medicines division reported revenue of ₹ 2,459 Cr, during H1FY27, increased by 13%
- Q2 Revenue of ₹ 1,302 Cr; increased by 15% Y/Y, primarily driven by continued order uptick, consistent volume and pricing resilience across broader ARV and US portfolio
- Capacity expansion and resource allocation going as per plan with focus on integrated CMO supplies
- KRKA JV updates: Finished formulation site progress on track. Phase-I production blocks to be opened in mid-2027 focusing on High Potent and General OSD capability
- Product filings update:
  - DMF filings: Cumulatively, 92 DMFs filed till date
  - Developed market FDF filings: 2 product dossiers filed and a total of 2 approvals received (including Tentative approvals) in H1. Cumulatively, 96 products filed till date

R&D and Other Highlights:

- Total R&D investments including capex R&D for H1FY27 was ₹ 183 Cr (4.3% of Revenue), increased by 34% Y/Y due to development efforts toward building Advanced Biologics infrastructure (Gene Therapy/Antibody Drug Conjugates)
- Total R&D investments for Q2 was ₹ 65 Cr (2.9% of Revenue)

- Laurus Labs entered into definitive agreement to acquire 60% stake in Canada based Galenvs Science, specialized in Oligonucleotide and precision magnetic nanoparticles. The investment strengthens technology platform to deliver a seamless, end-to-end oligonucleotide offering by combining Galenvs early-stage development, conjugation, advanced purification, and fill-finish with Laurus Lab's large-scale manufacturing expertise in complex chemistry, fermentation, peptides, analytical science, and sterile drug formulation. The transaction is expected to expand Laurus position in fast growing oligonucleotide market (+22 - 24% CAGR over 2025-2030)
- Laurus Labs entered into definitive agreement to acquire 52% stake in SI &C Resins, peptide-resin technology focused company. The transaction enhances longer term Supply chain security and peptides manufacturing competitiveness by bringing in-house peptide solid support resins and chromatography stationary phases

Quality and ESG Highlights:

- We completed 59 Quality audits in H1. Company has successfully passed audit inspections without critical findings
- Sustained recognition by leading global ratings agencies and also making operational progress against our SBTi-validated near-term GHG reduction targets

Earnings Conference Call

The company will organize a conference call on Thursday, October 29, 2026 - 5:00 pm IST to discuss Q2 & H1 FY27 results followed by an interactive Q&A session from participants. All participants may join the call by dialing below numbers OR by using Diamond Pass link

Conference Dial-in	
Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 101 2045
Hong Kong	+800 964 448
USA	+1 866 746 2133
UK	+0 808 101 1573
Express Join with Diamond Pass	**Click here to register**

Transcript of the conference call will be available on the Company's website: www.lauruslabs.com

END

Media Relations

Karthik C
T +91 40 3980 4380 | 9030088669
mediarelations@lauruslabs.com

Investors Relations

Vivek Kumar
T +91 40 3980 4366
investorrelations@lauruslabs.com

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions.

The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its "Smart and Green" chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a "BBB" MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices.

Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle "Chemistry for Better Living," Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

For more information visit **www.lauruslabs.com**

Follow @ Laurus Labs on **LinkedIn** | **Twitter** | **Facebook** | **Instagram**

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.